Septerna reports Q1 EPS (19c), consensus (27c)

Reports Q1 revenue $26.52M, consensus $15.09M. “In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the initiation of our Phase 1 clinical trial for SEP-479,” said Jeffrey Finer, chief executive officer and co-founder of Septerna (SEPN). “These advances further validate our Native Complex Platform and its ability to efficiently generate differentiated oral small molecules against historically challenging GPCR targets. As our clinical programs continue to advance, we believe Septerna is increasingly well positioned to unlock the broad therapeutic potential of GPCR-targeted medicines for patients with significant unmet need.”